Michael Zinner: A primary screening option for colorectal cancer
Michael Zinner, CEO and Executive Medical Director of Miami Cancer Institute and Baptist Health Cancer Care, shared a post on LinkedIn:
“Prioritizing early cancer detection is crucial to increasing relative survival rates. I was elated to learn of Guardant Health’s first approved blood test, Shield, which is considered a primary screening option for colorectal cancer and a paramount advancement in early detection and treatment.
Colorectal cancer remains a significant health concern, but with advancements like these, we are making momentous strides toward more effective screening and treatment.
Among the numerous medical professionals commenting on the test, from results and comparisons to its limitations, our very own Dr. Stephen Grabelsky, with Lynn Cancer Institute, part of Baptist Health Cancer Care, shared his insightful details on the sensitivity and intended use of this innovative test.
This development underscores the critical importance of early detection in the fight against cancer and, most importantly, in saving lives. As a leader in the healthcare community, I am committed to advocating for the best possible care for all patients, and I encourage all to read the piece below and prioritize regular cancer screenings.
Thank you, Fox News Media, for spotlighting this critical breakthrough.
Source: Michael Zinner/LinkedIn